Trial Profile
The study of atherosclerosis with ramipril and rosiglitazone.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Aug 2023
Price :
$35
*
At a glance
- Drugs Ramipril (Primary) ; Rosiglitazone (Primary)
- Indications Atherosclerosis; Glucose intolerance
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms STARR
- 02 Jun 2009 Primary endpoint 'Intima media thickness' has not been met, according to results published in the Journal of the American College of Cardiology.
- 02 Jun 2009 Results published in the Journal of the American College of Cardiology.
- 24 Aug 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.